Elecoglipron: AstraZeneca's Oral GLP-1 Pill Hits ~11.8% Weight Loss and Heads to Phase 3 (August 26, 2026)
Table of Contents
- The next frontier for GLP-1: a pill you can actually scale
- What elecoglipron is - and why 'small molecule' matters
- VISTA: about 11.8% weight loss at 36 weeks - and still falling
- SOLSTICE: strong glucose control, and a peek versus oral semaglutide
- Tolerability: classic GLP-1, mostly manageable
- How the numbers stack up in the oral GLP-1 race
- The Phase 3 program: EMBOLD, ELUMINATE, and outcomes
- What's still unproven
- Where it fits on PepTracker
- Bottom line
The next frontier for GLP-1: a pill you can actually scale
Semaglutide and tirzepatide reshaped obesity and diabetes care - but they are peptides, which means injections (or an oral peptide taken under strict fasting rules), complex manufacturing, and supply that has repeatedly struggled to keep up with demand. With nearly three billion people worldwide living with obesity or overweight, the industry's holy grail is a simple daily tablet that works nearly as well and can be mass-produced cheaply. That is exactly the bet behind elecoglipron (development codes AZD5004 / ECC5004), AstraZeneca's investigational oral small-molecule GLP-1 receptor agonist, which on June 8, 2026 became the company's headline metabolic asset when it moved into a large Phase 3 program on the strength of two positive Phase 2b trials.
What elecoglipron is - and why 'small molecule' matters
GLP-1 receptor agonists lower blood sugar and body weight by mimicking the gut hormone glucagon-like peptide-1: they boost glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and act on appetite centers in the brain. The approved drugs do this with peptides. Elecoglipron instead is a non-peptide chemical molecule that binds and switches on the same GLP-1 receptor. That difference is the whole point: a small molecule can be formulated as a convenient once-daily tablet with no food or fasting restrictions, and it can be synthesized at industrial scale far more cheaply than a peptide. Elecoglipron was originally discovered by Eccogene (as ECC5004) and licensed by AstraZeneca in 2023; it now sits alongside Eli Lilly's orforglipron, aleniglipron, Pfizer's danuglipron and others in the increasingly crowded oral small-molecule GLP-1 race.
VISTA: about 11.8% weight loss at 36 weeks - and still falling
VISTA was a global, randomized, double-blind Phase 2b trial in 310 adults with obesity or overweight and at least one weight-related comorbidity (mean baseline weight 106.9 kg) across seven countries. It tested fixed low doses (5 mg, 15 mg) and escalated regimens (50 mg, 75 mg) once daily against placebo. The 75 mg regimen hit both co-primary endpoints: average body-weight reduction of 10.5% at 26 weeks versus just 0.6% on placebo, and up to 88.8% of participants achieving at least 5% weight loss at 26 weeks. Crucially, the weight-loss curve had not plateaued - it kept dropping to about 11.8% by week 36 (versus 0.3% placebo), with roughly 62% of the 75 mg group losing at least 10% and about 40% losing at least 15%. Exploratory analyses also showed lower blood pressure and lower C-reactive protein, a marker of systemic inflammation.
SOLSTICE: strong glucose control, and a peek versus oral semaglutide
The companion Phase 2b SOLSTICE trial enrolled 404 adults with type 2 diabetes (mean baseline HbA1c 7.9%) across nine countries. The primary endpoint was HbA1c change at 26 weeks, and elecoglipron 75 mg delivered a 1.9% reduction versus 0.2% on placebo. About 90% of participants on that regimen reached an HbA1c below 7% and 85% got to 6.5% or lower - the guideline targets clinicians care about - while also losing 7.7% of body weight. SOLSTICE included an open-label oral semaglutide 14 mg arm for exploratory comparison, and elecoglipron came out numerically ahead of it on both HbA1c (-1.9% vs -1.3%) and weight (-7.7% vs -5.1%). That is not a powered head-to-head test, so it should be read as encouraging rather than definitive.
Tolerability: classic GLP-1, mostly manageable
Elecoglipron's safety profile looked like the GLP-1 class it belongs to. Adverse events were predominantly gastrointestinal and mild to moderate. In VISTA at 75 mg versus placebo, that meant nausea (55% vs 20%), constipation (41% vs 6%), diarrhea (35% vs 25%), and vomiting (29% vs 5%); rates were lower in the diabetes trial. Discontinuations for adverse events were infrequent in both studies, no liver safety signals emerged, and hypoglycemia was uncommon in the diabetes population. Notably, AstraZeneca said the Phase 2 tolerability data were used to refine the dose-escalation schedule for Phase 3 - a common lever for smoothing out early GI side effects.
How the numbers stack up in the oral GLP-1 race
Elecoglipron's roughly 11.8% weight loss at 36 weeks places it among the more potent oral small-molecule GLP-1 candidates reported so far, and its non-plateauing curve hints at more to come with longer dosing. But context matters: cross-trial comparisons are unreliable, follow-up here is short (26-36 weeks), and the field is fast-moving - orforglipron is already FDA-approved for weight management, and aleniglipron, danuglipron and others are advancing their own datasets. Injectable benchmarks like tirzepatide still set a high bar on absolute weight loss. The real differentiators for the oral class may end up being tolerability, durability, and - given the scale of the obesity population - manufacturing and price.
The Phase 3 program: EMBOLD, ELUMINATE, and outcomes
AstraZeneca is not treating elecoglipron as a single-indication drug. The Phase 3 program includes the EMBOLD trials evaluating it in obesity or overweight (with and without type 2 diabetes) and the ELUMINATE trials in type 2 diabetes, testing elecoglipron both as monotherapy and in combination with the SGLT2 inhibitor dapagliflozin - a combination aimed at the overlapping cardiovascular, renal and metabolic burden these patients carry. On top of those, AstraZeneca plans dedicated long-term cardiovascular and kidney outcome trials. Those outcome studies are what ultimately separate a good weight-loss number from a medicine proven to prevent heart attacks, strokes and kidney decline.
What's still unproven
It is worth being clear-eyed. Elecoglipron is investigational and not approved anywhere. Its data come from Phase 2b trials of 26-36 weeks, so long-term efficacy, durability and safety are unknown. Head-to-head superiority over semaglutide or tirzepatide has not been established. Cardiovascular and kidney benefit - the endpoints that justify the biggest claims - remain to be tested. And the usual GLP-1 class considerations (pancreatitis, gallbladder disease, and rodent-derived thyroid C-cell tumor warnings) apply. As always: there is no legitimate consumer supply of elecoglipron, and anything sold under that name or its codes outside a clinical trial is unverified.
Where it fits on PepTracker
Elecoglipron joins PepTracker's oral small-molecule GLP-1 cluster, cross-linked with orforglipron, aleniglipron, danuglipron and conveglipron, and set against the injectable peptide benchmarks semaglutide, ecnoglutide and efpeglenatide. Reading those entries side by side is the best way to see how the pill era of GLP-1 medicine is taking shape - who is fastest, who is best tolerated, and who ultimately proves outcomes.
Bottom line
Elecoglipron is one of the strongest signals yet that oral small-molecule GLP-1 pills can approach the metabolic punch of injected peptides: about 11.8% weight loss at 36 weeks, a 1.9% HbA1c drop, class-typical tolerability, and a numerical edge over oral semaglutide in its diabetes trial. The move into the EMBOLD and ELUMINATE Phase 3 programs plus cardiovascular and kidney outcome trials is the real test. If those confirm the efficacy and show hard-outcome benefit, a cheap, scalable daily pill could meaningfully widen access to GLP-1 therapy. This article is educational and not medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Elecoglipron moves to Phase III programme - AstraZeneca press release (June 8, 2026) Source
- [2] Elecoglipron in adults with obesity or overweight (VISTA): phase 2 randomised trial - The Lancet Source
- [3] Elecoglipron (VISTA) - PubMed Source
- [4] ADA: AstraZeneca's oral GLP-1 shows competitive efficacy in phase 2 - Fierce Biotech Source
- [5] Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data - HCPLive Source
- [6] AstraZeneca's New Oral GLP-1 Led to 10.5% Weight Loss - Healthline Source
Related Articles
Eli Lilly's Foundayo (orforglipron) becomes the first oral non-peptide GLP-1 approved for weight loss, CagriSema shows superiority over semaglutide alone in REIMAGINE-2, semaglutide enters Alzheimer's Phase 3 trials, tirzepatide reduces sleep apnea events, and the FDA peptide reclassification moves forward.
Structure Therapeutics' aleniglipron posts up to 15.3% weight loss in Phase 2, readying Phase 3 to compete with Foundayo. Retatrutide's pivotal TRIUMPH-1 obesity readout is expected any day. Pemvidutide's MASH data reaches The Lancet with Breakthrough Therapy Designation. And AI-designed antimicrobial peptides advance toward clinics.
The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026
Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.